



1/2
SEQUENCE LISTING

<110> DUBOIS, Claire

5 <120> USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT
OF INFLAMMATORY OR MATRIX REMODELLING DISEASES

<130> 85761-28

10 <140> US 09/885,914
<141> 2001-06-22

<150> US 60/213,995
<151> 2000-06-26

15 <150> CA 2,312,109
<151> 2000-06-23

<160> 3

20 <170> PatentIn version 3.2

<210> 1
<211> 4

25 <212> PRT
<213> Homo sapiens

<220>
30 <221> SITE
<222> (1)..(4)
<223> Reactive site of alphas-antitrypsin

<400> 1

35 Ala Ile Pro Met
1

40 <210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

45 <220>
<223> Variant of Homo sapiens alphas-antitrypsin reactive site

<220>
50 <221> MUTAGEN
<222> (1)..(1)
<223> Ala355 to Arg355 variant of reactive site of alphas-antitrypsin

<220>
55 <221> MUTAGEN
<222> (4)..(4)
<223> Met358 to Arg358 variant of reactive site of alphas-antitrypsin

<400> 2

Arg Ile Pro Arg

1

<210> 3

<211> 4

<212> PRT

10 <213> Artificial Sequence

<220>

<223> Synthetic peptide

15

<220>

<221> MOD_RES

<222> (1)..(1)

20 <223> Arg at position 1 is modified at its amino group with a decanoyl group

<220>

<221> MOD_RES

<222> (4)..(4)

25 <223> Arg at position 4 is modified at its carboxyl group with a -CH₂Cl group

<400> 3

30 Arg Val Lys Arg

1